Shaurya Srivastava
Lansing, MINPI 1790301349
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (57.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Abbott at 58.7% of the total. Reporting peaked in 2024 at $5,478 and has fallen 63.1% since, to $2,021 in 2025.
Across 151 payments — averaging $76.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Medtronic$867
- Amgen$617
- AstraZeneca$537
- Boston Scientific$462
- Pfizer$419
- plus $2K from 16 others
What the payments were for
- Grants$6,65057%
- Travel & lodging$7567%
- Food & beverage$4,09135%
- Education$951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $6,801 |
| Medtronic | 5 | $867 |
| Amgen | 27 | $617 |
| AstraZeneca | 16 | $537 |
| Boston Scientific | 11 | $462 |
| Pfizer | 19 | $419 |
| E.r. Squibb & Sons, L.L.C. | 13 | $352 |
| Boehringer Ingelheim | 11 | $235 |
| Actelion Pharmaceuticals US, Inc. | 6 | $228 |
| Alnylam Pharmaceuticals Inc. | 5 | $216 |
| Novartis | 7 | $146 |
| Bayer | 8 | $140 |
| Edwards Lifesciences | 2 | $116 |
| Shockwave Medical, Inc | 1 | $80 |
| Johnson & Johnson | 3 | $73 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $69 |
| Bridgebio Pharma, Inc. | 3 | $65 |
| Abiomed | 1 | $64 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $35 |
| Terumo Medical Corporation | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Merck | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $24,223 |
| Atorvastatin Calcium | 56 | $1,364 |
| Rosuvastatin Calcium | 34 | $1,332 |
| ClopidogrelClopidogrel Bisulfate | 27 | $480 |
| Metoprolol Succinate | 26 | $386 |
| Amlodipine Besylate | 26 | $352 |
| Losartan Potassium | 31 | $328 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $326 |
| Carvedilol | 24 | $286 |
| Spironolactone | 16 | $143 |
| Furosemide | 14 | $117 |
| Lisinopril | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $419 | $24,22336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Michiganon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.